Something to consider: at today's rock bottom share prices, Juvenescence essentially has claim to nearly all of AgeX's meager ~$25mm market cap between its convertible debt and massive share ownership. Every time Juvenescence deploys another year's worth of $7mm in precious capital to fund AgeX operating expenses, it would stand to reason they believe AgeX will not only be worth another $7mm some day (18 cents per share), but also provide a meaningful return on the $23mm in debt they will have deployed in the project by around year end, not to mention express value to potential IPO investors.
B
New Senior Accountant. New Board Chair. New chapter for AgeX?
What we need is a good old fashioned sellers strike. There was a 20%+ spread between bid and ask this morning. Far be it from me to say anyone should't take a profit if they want/need to, but this stock is just begging for some buyers pressure, see also, @Bob's post from yesterday.
B
Today we saw the all-time record low daily volume at 3165 shares. Of course, there is little difference between that and a few thousand more as we have often seen over the past month. My theory? Many have stocked up here near the all-time lows, and the cupboard is bare.
B
The volume beast has slinked away to the shadows again. We just posted the all-time low weekly volume at 76k shares this week, easily shattering the previous low of 110k from 2 weeks ago. Interestingly the XBI (S&P Biotech ETF) had its 3rd highest ever volume week in rather stark contrast to AGE, not to mention XBI is just 1 bad day from its Covid panic low. But wait, did I forget to mention the biggest news out of AgeX in 2022: they are hiring an accountant. This week on their website they posted a job in their brand new Careers tab for a Senior Accountant: https://www.agexinc.com/careers/ My favorite listed duty? "Daily posting of vendor invoices (to hire AP accountant when volume increases.)" That sure would be a lot bean counters for a staff of 6. Almost sounds like a big shipment of beans coming their way soon.
AgeX Therapeutics | Careers
www.agexinc.com
B
Record low weekly volume on AGE last week at 110k shares. That comes the week after the third lowest week ever at 140k shares. Feels like a trading halt courtesy of the market itself. Can't wait until the announcement after which market agrees to resume trading.
B
Let's revisit something I've been thinking since AgeX got spun out 3.5(!) years ago. AgeX *still* does not have a lot of shares available for retail holders, appx 14mm by my calculations in the table below (about $12.5mm currently). That's only enough room for 100 investors at $125k each. If AgeX (or Partial Reprogramming) ever gets some serious credibility and/or press, it wouldn't take many diamond hands holders to lock the float up for the only existing retail pure play on it. And arguably, this story (let's all get healthier/younger) could have far more general appeal than GME (let's fry the shorts) or BTC (let's take over global trade). Should this come to pass, what would we call ourselves? Eternals? Lifers? Immortalists? Westies? It's a tricky business. Much easier to come up with the obvious corporate softball team mascot: the AgeX Axolotls.
AgeX Ownership Shares Percent Current Float 37,940,000 100% Juvenescence 16,837,817 44% Broadwood Capital 2,003,446 8% Institutional Holders 2,769,104 7% Alfred Kingsley 700,000 2% Total Held Tightly 23,310,367 61% Free to Trade 14,629,633 39%
Market responds to AGE Q1/22 Earnings by...let me check my notes...ahhhh yes, with trading volumes that are less than AGE's revenue of $5000 by 2:08 EST.
By all accounts AGE should have been cut in half today, yet, silence. All of this makes me say... $27M Market Cap my rosy rear end. We're clearly going higher, as we're clearly not going down.
It seems there's a strong correlation between AGEX trading volume and comment volume here. Everyone has about the number of shares they want and not much to say about it. I miss the old days!
In this #webinar, Dr Michael West, a bioentrepreneur and CEO of AgeX Therapeutics, discussed the work of AgeX Therapeutics, their mission and plan to extend ...
In this #webinar, Dr Michael West, a bioentrepreneur and CEO of AgeX Therapeutics, discussed the work of AgeX Therapeutics, their mission and plan to extend ...
AgeX Ownership Shares Percent
Current Float 37,940,000 100%
Juvenescence 16,837,817 44%
Broadwood Capital 2,003,446 8%
Institutional Holders 2,769,104 7%
Alfred Kingsley 700,000 2%
Total Held Tightly 23,310,367 61%
Free to Trade 14,629,633 39%
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=AgeX&OS=AgeX&RS=AgeX
By all accounts AGE should have been cut in half today, yet, silence. All of this makes me say... $27M Market Cap my rosy rear end. We're clearly going higher, as we're clearly not going down.
https://investors.agexinc.com/news/news-details/2022/AgeX-Therapeutics-Reports-Fourth-Quarter-and-Annual-2021-Financial-Results/default.aspx
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=3&f=G&l=50&co1=AND&d=PG01&s1=Agex&OS=Agex&RS=Agex
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=AND&d=PG01&s1=Agex&OS=Agex&RS=Agex
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=Agex&OS=Agex&RS=Agex
https://m.youtube.com/watch?v=P4_xKBBFR0M
https://mobile.twitter.com/BKennedy_aging/status/1498597915547344896